Alvotech and Dr. Reddy’s Laboratories announce they have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva (denosumab), which are indicated for the treatment of various diseases including osteoporosis in postmenopausal women and the prevention of skeletal-related events in adults with advanced malignancies. Alvotech will be responsible for the development and manufacturing of the product, while Dr. Reddy’s will oversee the registration and commercialization of the product in the applicable markets.